Fundraising Fox
Ayuvant
1 known investors
Find your way into Ayuvant
Sign up to see every warm intro you have to Ayuvant
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ayuvant team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Ayuvant is developing an RNA-nanoparticle immunotherapy designed to direct the immune system to recognize and attack cancer cells. The platform targets patients who do not respond to existing immune checkpoint inhibitors and has shown antitumor activity in checkpoint-inhibitor-resistant models.
Founders & leadership
LC
Lucas CzentnerCo-Founder | CEOHe worked in immunotherapy development and commercialization at pharmaceutical companies and earned a Ph.D. in cancer immunotherapies from Utrecht University.
Investors · 1
Frequently asked questions
- What does Ayuvant do?
- Ayuvant is developing an RNA-nanoparticle immunotherapy designed to direct the immune system to recognize and attack cancer cells. The platform targets patients who do not respond to existing immune checkpoint inhibitors and has shown antitumor activity in checkpoint-inhibitor-resistant models.
- Who founded Ayuvant?
- Ayuvant was founded by Lucas Czentner.
- Who are Ayuvant's investors?
- Ayuvant's investors include AIR Capital.